# Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review | This GLP An umbrella review of ten GLP-1 and atrial fibrillation meta-analyses found substantial overlap, low confidence throughout, and identical evidence bases giving different answers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review Two meta-analyses of the same six trials published pooled hazard ratios of 0.58 and 0.78. Nothing separated them but the choices their authors made. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Two reviews. The same six trials. 100% overlap. · review A · 0.58 · review B · 0.78 · 1.0 · The difference is analytic choices, not data. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Ten meta-analyses of GLP-1 drugs and atrial fibrillation were appraised together in an umbrella review. - Two of them shared an identical six-study base and reported pooled hazard ratios of 0.58 and 0.78. - Across reviews, incident AF estimates ranged from an odds ratio of 0.54 to 0.83. - Overlap between reviews was substantial: 43.8% for recurrence, 34.1% among the semaglutide-only incident reviews. - Confidence was low in five reviews and critically low in four. None reached moderate or high. Ten meta-analyses agreeing with each other looks like a settled question. This umbrella review went and checked what they were made of, and the answer is that they are largely made of the same trials — which is the difference between [counting studies and counting independent observations](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## The pair that settles it Two of the three reviews of post-ablation atrial fibrillation recurrence included exactly the same six primary studies — a pairwise corrected covered area of 100%. [\[1\]](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials#ref-1) One reported a pooled hazard ratio of 0.58, 95% CI 0.42 to 0.79. The other reported 0.78, 95% CI 0.61 to 0.99. Identical evidence, different published answers. Nothing separates them except what their authors chose: which comparator, which statistical model, which population. A reader who found one of those papers would come away with a meaningfully different impression from a reader who found the other — which is what [a conclusion detached from its data](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease) looks like when it happens twice from one dataset. What the gradient was made of The umbrella review traced where the disagreement came from, and it tracked three analytic features. Estimates were smaller against an active comparator than against placebo, smaller under a fixed-effect model than a random-effects one, and smaller in type 2 diabetes populations than in obesity populations. Each of those is a defensible decision and none of them is a finding about the drug. The spread between meta-analyses is partly a map of the decisions their authors made. ## How much of the literature is one literature Corrected covered area measures how much the primary studies inside a set of reviews overlap. It came to 43.8% across the three recurrence reviews, 34.1% across the five semaglutide-only reviews of incident AF, and 22.5% across all six incident-AF reviews. So when these papers agree, that agreement is substantially a shared base rather than independent replication, which is the authors’ own conclusion. Ten citations pointing the same way is not ten pieces of evidence — the same illusion as [a pooled figure standing in for consensus](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## The quality appraisal Every review was independently appraised twice on a standard instrument. Five came out at low confidence and four at critically low. None reached moderate or high. That is a striking result for a question with ten published syntheses. Quantity of reviews has no relationship to the certainty they can deliver, and the effect estimates still spread from an odds ratio of 0.54, 95% CI 0.39 to 0.77, up to 0.83, 95% CI 0.70 to 0.98 — intervals that overlap but describe quite different sized benefits, as [the underlying trial-level evidence](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) also shows. ## What this does not say That the effect is not real. The authors’ conclusion is that GLP-1 drugs are plausibly associated with lower atrial fibrillation burden, with certainty low for new cases and very low for recurrence after ablation. What they ask for is adequately powered randomized trials with AF endpoints that are adjudicated and systematically monitored — because a rhythm problem that is often silent is only counted when somebody looks for it, and how hard a study looks is another choice that moves the number. ## Frequently asked How can two meta-analyses of the same studies disagree? Through analytic choices. The estimates tracked which comparator was used, whether a fixed or random-effects model was applied, and which population was studied — none of which is a finding about the drug. Do GLP-1 drugs reduce atrial fibrillation? Plausibly, according to the authors, with certainty rated low for new cases and very low for recurrence after ablation. Adequately powered trials with monitored AF endpoints are what they ask for. Why does overlap between reviews matter? Because agreement between reviews that share most of their primary trials is not independent replication. Overlap ran to 43.8% across the recurrence reviews. How good were the reviews? Five were rated low confidence and four critically low on a standard appraisal instrument. None reached moderate or high. ## Sources 1. \[1\] Ramzy D, et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses Cureus. [PMID 42668799](https://pubmed.ncbi.nlm.nih.gov/42668799/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)